ZIM Laboratories is a research-driven pharmaceutical company that makes complex generic medicines in easy-to-take oral forms - tablets, capsules, powders and dissolving films - using its own patented, non-infringing manufacturing technologies. Founded in 1984 by a pharmaceutical chemist who returned to Nagpur to build the business, it has evolved from a government tender supplier into a global exporter of differentiated generics across more than 50 countries. The recurring approach is to avoid plain-vanilla generics that compete on price, and instead develop “smarter generics or super generics” - products with unique delivery mechanisms that can be created faster and cheaper than novel drugs, then licensed to local partners who handle the selling. # Business segments Three engines at different stages - a differentiated generics cash cow that supplies intermediates and finished pills to partners worldwide, a high-value innovation pipeline of next-generation complex molecules, and a consumer-wellness bet built on the same film technology - all fed by a single R&D and manufacturing backbone. ## 1. Differentiated generic pharmaceuticals: the partner-supply engine that funds everything else **ZIM makes complex oral-solid medicines and the intermediates that go into them, then licenses the dossiers and supplies the products to distribution partners who take them to market - it owns the factory and the science, not the sales force.** - **Two product forms, one model** - the business sells Pre-Formulation Intermediates (pellets, granules and taste-masked powders that clients turn into finished drugs) and Finished Formulations (tablets, capsules, dry syrups and oral thin films ready for pharmacy shelves); PFI targets countries that restrict direct imports of finished medicines, while FF goes to markets where ZIM’s partners register the products under their own or ZIM’s brand. - **No feet on the street** - instead of building its own sales force, ZIM uses a business-development team to find local distributors and marketing companies, transfers the Marketing Authorisation to them, and signs long-term supply agreements that last “as long as the business will be there”; the technology never leaves ZIM’s own plant. - **The moat is non-infringing know-how** - four proprietary technology platforms (with names like Micro-Emulsion Coating and Pellet Cold Forming) let ZIM make differentiated generics without stepping on existing patents, so partners get a product with a competitive edge and ZIM avoids the price wars of common generics. - **Three plants, one campus** - all manufacturing happens in Nagpur across a 100,000 sq. ft. general oral-dosage facility, a dedicated cephalosporin block and a compact oral-thin-film plant; together they hold WHO-GMP and ISO certifications, though EU-GMP accreditation was paused during FY26 after an audit and is being remediated. ## 2. New Innovative Products: the high-stakes pipeline of first-to-market complex generics **These are next-generation, non-infringing versions of large-market drugs - developed in-house, filed mainly in Europe, and designed to be among the first generics available when patents expire.** - **Twelve shots on goal** - ZIM has fully developed a dozen NIP molecules targeting markets worth hundreds of millions to several billion dollars each, spanning urology, gastrointestinal, anti-coagulant, central-nervous-system, rheumatoid-arthritis, anti-infective, analgesics/pain and skin-disorders therapies. - **Europe is the proving ground** - eight NIPs have been filed in the European Union so far, and three have already received Marketing Authorisations there: a blood-thinner (Dabigatran Etexilate) approved in Italy, a multiple-sclerosis drug (Di-Methyl Fumarate) and an anti-infective oral suspension (Azithromycin). - **Revenue comes from licensing first, supply later** - the model earns dossier-licensing fees upfront and then manufacturing-and-supply revenue once the partner launches; in FY26 NIP and dossier-licensing income together contributed about ₹267 million, or 7% of total operating income. - **One product already has Indian regulatory approval** - a fixed-dose combination of Naproxen and Esomeprazole in a single capsule, using ZIM’s delayed-release mini-tablet and pellet technology, received Indian regulatory approval in late 2025 and is headed for commercial launch through a domestic pharmaceutical company. ## 3. Oral Thin Films: the patient-friendly format that opens both pharma and wellness markets **ZIM’s patented Thinoral® technology turns medicines and supplements into postage-stamp-sized strips that dissolve instantly on the tongue - no water, no swallowing, and a growing list of branded deals in Europe, Latin America and Australia.** - **A platform, not a single product** - the OTF engine spans prescription drugs (like Rizatriptan for migraines and Sildenafil for erectile dysfunction), nutraceuticals (Vitamin D3, Melatonin, Vitamin B12) and a pipeline of sublingual and mucoadhesive films that absorb directly through the mouth’s lining. - **Technology out-licensing is the newest lever** - in a landmark 2025 deal, ZIM licensed its ThinOral® know-how to UAE-based Globalpharma, which will register and eventually manufacture ten OTF products locally using ZIM’s ready-to-use powder mixes; an earlier exclusive deal put Vitamin D3 film into Brazil’s number-one vitamin-D brand. - **Regulated-market beachheads are opening** - the first European commercial order (Sildenafil film) shipped to Italy and Malta in FY24; Australia granted its first Marketing Authorisation for Rizatriptan Benzoate Orally Disintegrating Strips in mid-2025; and a co-development partner, Neuraxpharm, secured an EU-wide approval for Buprenorphine sublingual films. - **A dedicated plant with a hiccup** - the 6,300 sq. ft. OTF facility can produce 324 million strips a year and holds ISO 9001 and NSF-ANSI 455-2 certifications, though an EU inspection in early FY26 raised observations that deferred a German launch; corrective actions were submitted and accepted. ## 4. Nutraceuticals: the consumer-wellness extension of the same factory and science **ZIM takes the pellet and film technologies built for prescription drugs and applies them to vitamins and dietary supplements, selling under its own ZimUNaT brand through e-commerce and government channels.** - **Same dosage forms, different customer** - the nutraceutical range uses pellets-in-capsules and oral thin films to deliver supplements for eye care, cognition, blood-sugar support, anti-ageing and more; the business grew out of supplying distinctive PFIs to nutraceutical clients and now sells finished branded products directly. - **Omnichannel, but asset-light** - ZimUNaT products are sold on Indian e-commerce platforms like Tata 1mg, Amazon and Flipkart, and the company also supplies government procurement schemes; it is building an omnichannel strategy that integrates offline distribution networks. - **Certified for quality** - the nutraceutical operation holds NSF GMP certification for dietary supplements and is registered with the US FDA, and a recent capital-expenditure project added a liquid-in-pellet technology suite to expand the product range. # Group structure and partners **ZIM operates through a single listed entity in India with a ring of small, wholly owned subsidiaries in the UAE, Europe, Australia and soon Chile - each one exists to hold registrations, manage regulatory filings and get products into local markets.** - **Latvia for Europe** - SIA ZIM Laboratories Limited manages product registrations and marketing in the EU, and has secured Manufacturing and Marketing Authorisations from Portuguese and Italian regulators for ZIM’s OTF and NIP products. - **Australia for Oceania** - ZIMTAS Pty Ltd, now 99.96% owned, holds Marketing Authorisations for two products and received the company’s first Australian approval in mid-2025. - **Two Indian subsidiaries for focus** - ZIM Health Technologies Limited acts as an extended R&D arm, while ZIM Thinorals Private Limited was incorporated to house the OTF business and is yet to commence operations. - **A newly formed advisory board** - constituted in March 2026, it brings three heavyweights with decades of leadership at GSK Pharma, UCB Pharma and private-equity advisory to guide strategy, without executive powers.